Inosine Pranobex — Is a Single Positive Trial Enough?
- 21 June 1990
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (25) , 1807-1809
- https://doi.org/10.1056/nejm199006213222509
Abstract
Recognition of the myriad immunologic defects associated with human immunodeficiency virus (HIV) infection has stimulated the development of novel approaches to its treatment. To date, the most effective treatments have been antiviral agents directed against HIV itself, such as zidovudine (formerly AZT, or azidothymidine). However, active efforts continue in the search for agents to restore or improve the defective immune systems of persons infected with HIV. Although the distinction between immunomodulatory and antiretroviral therapy is not always clear, the possibility of a combined approach is conceptually exciting. The clinical testing of potential immunomodulators increases the complexity of drug development by . . .Keywords
This publication has 7 references indexed in Scilit:
- The Efficacy of Inosine Pranobex in Preventing the Acquired Immunodeficiency Syndrome in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric studyMedical Oncology and Tumor Pharmacotherapy, 1989
- Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1Antimicrobial Agents and Chemotherapy, 1988
- Inosine PranobexDrugs, 1986
- A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathyClinical Immunology and Immunopathology, 1986
- In-vivo Immunomodulation by Isoprinosine in Patients with the Acquired Immunodeficiency Syndrome and Related ComplexesAnnals of Internal Medicine, 1984